Digtal health company ResApp Health (ASX:RAP)
has achieved CE Mark certification for the company’s wearable device as a Class I medical device accessory.
This allows ResApp to progress the manufacture and sale of the device in Europe.
ResApp’s wearable device allows for continuous 24-hour patient monitoring using cough audio.
Cough frequency is a key factor in respiratory disease progression and management, and may be an important outcome measure in clinical trials involving a broad range of disease states where cough is implicated.
Shares in ResApp Health (ASX:RAP)
are trading 1.8 per cent higher at 6 cents.